Amgen announced the U.S. Food and Drug Administration (FDA) has granted priority review designation for ivabradine for the treatment of chronic heart failure (HF). Ivabradine is an oral drug that inhibits the If current ("funny" current) in the sinoatrial node, the body's cardiac pacemaker. Ivabradine works to slow the heart rate without negative effects on myocardial contractility or ventricular repolarization. Heart failure is a common condition that affects approximately 26 million worldwide, including approximately 5.1 million people in the U.S.
No comments:
Post a Comment